Loading company…
Xunmeng Biotechnology is developing engineered cell therapies for cardiovascular, inflammatory and kidney diseases.
Xunmeng Biotechnology is developing an engineered cell therapy platform for cardiovascular diseases, inflammatory disorders and chronic kidney disease. Founded in 2025, the company is based in Shenzhen, China. In February 2026, it raised Angel funding from new investor Vinno Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in